Skip to main content
logo
Aerovate Therapeutics, Inc. (AVTE)
9.80
0.00 (0.00%)
Inactive · Last trade price on Apr 28, 2025

Aerovate Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-69.63-75.52-51.51-22.96-9.61
Depreciation & Amortization
0.280.10.070.020
Asset Writedown & Restructuring Costs
0.26----
Loss (Gain) From Sale of Investments
-2.25-3.06-0.910.02-
Stock-Based Compensation
11.3111.915.482.040.06
Other Operating Activities
----0.72
Change in Accounts Payable
-2.17-0.161.370.610.04
Change in Other Net Operating Assets
-99.966.39-7.120.94
Operating Cash Flow
-71.2-56.78-39.12-27.4-7.86
Operating Cash Flow Growth
-----

Investing Activities

Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Capital Expenditures
--0.14-0.2-0.18-
Investment in Securities
56.0312.027.12-113.25-
Investing Cash Flow
56.0311.886.93-113.43-

Financing Activities

Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Short-Term Debt Issued
----2.5
Total Debt Issued
----2.5
Net Debt Issued (Repaid)
----2.5
Issuance of Common Stock
25.7346.230.77126.950.01
Other Financing Activities
-0.31-0.23-0.37--
Financing Cash Flow
25.43460.4190.468.92

Net Cash Flow

Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Cash Flow
10.261.09-31.849.621.06

Free Cash Flow

Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Free Cash Flow
-71.2-56.92-39.32-27.58-7.86
Free Cash Flow Growth
-----
Free Cash Flow Per Share
-2.49-2.16-1.61-2.24-32.44
Levered Free Cash Flow
-48.54-28.72-18.2-18.78-4.53
Unlevered Free Cash Flow
-48.54-28.72-18.2-18.78-4.48
SEC Filings: 10-K · 10-Q